

Exosomes: A Novel Frontier in Endometriosis Treatment

ARTICLE INFO

Article Type

Editorial letter

Authors

Mohammad Reza Nateghi ^{1,2} 

1- Sarem Gynecology, Obstetrics and Infertility Research Center, Sarem Women's Hospital, Iran University of Medical Science (IUMS), Tehran, Iran.
2- Sarem Cell Research Center (SCRC), Sarem Women's Hospital, Tehran, Iran.

*Corresponding Authors:

Mohammad Reza Nateghi; Sarem Fertility & Infertility Research Center (SAFIR), Sarem Women's Hospital, Iran University of Medical Sciences (IUMS), Tehran, Iran.
Address: Sarem Women Hospital, Basij Square, Phase 3, Ekbatan Town, Tehran, Iran. Postal code: 1396956111, Phone: +98 (21) 44670888, Fax: +98 (21) 44670432.

Received: 22 June 2024

Accepted: 20 July 2024

Published: 09 December 2024

Article History

Editorial

Introduction: Exosomes, nanosized extracellular vesicles secreted by various cell types, have emerged as promising therapeutic agents in diverse medical fields, including oncology, neurology, and reproductive health. In recent years, their potential in treating endometriosis—a chronic inflammatory disorder affecting reproductive-aged women—has garnered significant attention. Endometriosis, characterized by the presence of endometrial-like tissue outside the uterus, is often accompanied by chronic pelvic pain, infertility, and systemic inflammation. Despite advancements in medical and surgical interventions, treatment remains suboptimal, underscoring the need for novel approaches [1-3].

Exosomes as Precision Therapeutics

Exosomes are rich in bioactive molecules, such as proteins, lipids, and nucleic acids, which can modulate cellular communication and immune responses. In endometriosis, their therapeutic potential lies in their ability to regulate inflammatory and fibrotic pathways, which are central to disease progression. Exosomes derived from mesenchymal stem cells (MSCs), for instance, exhibit potent anti-inflammatory, immunomodulatory, and anti-fibrotic properties. These effects are mediated through the transfer of microRNAs (miRNAs), cytokines, and growth factors that can reprogram the aberrant cellular environment of endometriotic lesions [4, 5].

Key Advances and Mechanisms

Recent preclinical studies highlight the efficacy of exosome-based therapies in animal models of endometriosis. MSC-derived exosomes have been shown to:

1. **Suppress Inflammation:** By downregulating pro-inflammatory cytokines such as IL-6 and TNF- α , they reduce the inflammatory milieu that perpetuates endometriotic lesions.
2. **Inhibit Angiogenesis:** Exosomal miRNAs like miR-16 and miR-150 can inhibit vascular endothelial growth factor (VEGF)-mediated angiogenesis, essential for lesion survival and growth.
3. **Promote Apoptosis:** Exosomes can induce apoptosis in ectopic endometrial cells, potentially reducing lesion size.
4. **Restore Immune Tolerance:** They modulate immune cells, such as macrophages and T regulatory cells, to restore immune balance in the peritoneal cavity [6, 7].
- 5.

Delivery and Clinical Translation

One of the most promising aspects of exosome-based therapy is its minimally invasive nature. Exosomes can be delivered via intravenous injection, direct application to affected tissues, or incorporation into hydrogel systems for sustained release. Moreover, advances in bioengineering allow for the customization of exosomes to enhance targeting and efficacy [8].

Future Directions

Despite their promise, exosome-based therapies for endometriosis are still in their infancy. Key challenges include large-scale production, standardization, and ensuring safety for clinical use. However, the potential for exosomes to provide a targeted, side-effect-minimized treatment alternative to current hormonal and surgical options is undeniable. The integration of exosome technology into endometriosis management could redefine the therapeutic landscape, offering hope to millions of women worldwide. With further

research, these nanoscale vesicles may well transition from bench to bedside, heralding a new era in reproductive medicine [9].

References

1. Beetler DJ, Di Florio DN, Bruno KA, Ikezu T, March KL, Cooper LT, Jr., et al., Extracellular vesicles as personalized medicine. *Mol Aspects Med*, 2023. 91: 101155.
2. Lopes D, Lopes J, Pereira-Silva M, Peixoto D, Rabiee N, Veiga F, et al., Bioengineered exosomal-membrane-camouflaged abiotic nanocarriers: neurodegenerative diseases, tissue engineering and regenerative medicine. *Military Medical Research*, 2023. 10(1): 19.
3. Chu X, Hou M, Li Y, Zhang Q, Wang S, Ma J, Extracellular vesicles in endometriosis: role and potential. *Frontiers in Endocrinology*, 2024. 15.
4. Wagner M, Hicks C, El-Omar E, Combes V, El-Assaad F, The Critical Role of Host and Bacterial Extracellular Vesicles in Endometriosis. *Biomedicines*, 2024. 12.(11)
5. Mosquera-Heredia MI, Morales LC, Vidal OM, Barceló E, Silvera-Redondo C, Vélez JI, et al., Exosomes: Potential Disease Biomarkers and New Therapeutic Targets. *Biomedicines*, 2021. 9.(8)
6. Wang Y, Ma H, Zhang X, Xiao X, Yang Z, The Increasing Diagnostic Role of Exosomes in Inflammatory Diseases to Leverage the Therapeutic Biomarkers. *J Inflamm Res*, 2024. 17: 5005-5024.
7. Skuratovskaia D, Vulf M, Khaziakhmatova O, Malashchenko V, Komar A, Shunkin E, et al., Exosome Limitations in the Treatment of Inflammatory Diseases. *Current Pharmaceutical Design*, 2021. 27(28): 3105-3121.
8. Fan M-H, Pi J-K, Zou C-Y, Jiang Y-L, Li Q-J, Zhang X-Z, et al., Hydrogel-exosome system in tissue engineering: A promising therapeutic strategy. *Bioactive Materials*, 2024. 38: 1-30.
9. Lee KWA, Chan LKW, Hung LC, Phoebe LKW, Park Y, Yi KH, Clinical Applications of Exosomes: A Critical Review. *Int J Mol Sci*, 2024. 25. (14)